2019-04-09 17:31
Biovica today announces its intention to carry out a directed new share issue of Class B shares of SEK 45-60 million, directed towards qualified investors in Sweden and internationally (the ”Directed New Share Issue”). Biovica has engaged...
2019-04-01 08:00
The patent is a kit-patent that protects against competing companies making copies of Biovicas product. The patent complements previous patent on the US market, which protects the method for the analyzis, making the protection even stronger. The patent...
2019-03-21 08:00
CEO’s comments Continued focus on commercialization of DiviTum® The focus of Biovica’s business plan is commercialization of DiviTum®, which will provide cancer patients with more personalized treatments leading to better outcomes...
2019-03-20 17:00
Below is a summary of the decisions taken at the Extra Shareholder’s Meeting. The Meeting resolved that the Chairman of the Board should be compensated with SEK 200,000 until the next Annual General Meeting. Lars Holmqvist was elected Chairman of...
2019-03-19 08:00
“We are glad to see that there is a demand for DiviTum® on the research market and an interest to include it in clinical trials in order to effectively follow up cancer treatments. We’re pleased that pharma companies see the value of our...
2019-03-18 08:00
How to participate: The live webcast and a recorded on-demand version including the presentation material will be accessible at: https://financialhearings.com/event/11802 Questions can be asked in writing via the webcast or verbally via the conference...
2019-03-04 07:56
Nasdaq First North Premier gives companies the opportunity to prepare for listing on the stock exchange’s main list by imposing higher demands on information disclosure, accounting principles and corporate governance. The requirements for being...
2019-02-28 07:57
The CDK 4/6 inhibitor, palbociclib, is Pfizer’s successful targeted therapy prescribed to more than 160 000 women with metastatic breast cancer around the world. The CDK 4/6 inhibitors, a class of targeted cancer therapies, interfere and target...
2019-02-22 08:00
Lars Holmqvist brings many years of experience and deep knowledge about the diagnostic business, which in combination with a strong international business network will add very valuable competence to Biovica and the ongoing commercialization process...
2019-02-04 07:57
Biovica has been ISO certified since 2010. The update means that Biovica continues to fulfil the regulatory requirements for the development, manufacturing and sale of the company’s product DiviTum®. The certification gives the company still...
>4,500
Numbers of patients in studies
28
Publications
22
Pharma Projects